Image Credit: STAT News
STAT+: Bristol’s Cobenfy disappoints as supplemental antipsychotic drug
The new schizophrenia drug didn’t provide additional benefits when given on top of standard-of-care therapy, Bristol Myers Squibb announced Tuesday.